Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Should AMTL be defined as a distinct diagnostic entity?

Jonathan Bond, MB BCh BAO, MRCPI, FRCPath, PhD, University College Dublin, Dublin, Ireland, discusses recent proposals to define acute myeloid/T-lymphoblastic leukemia (AMTL) as a distinct diagnostic entity. Prof. Bond reveals that the transcriptional overlap in interface acute leukemias provides support for the proposed classification of AMTL as a separate entity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.